智通财经APP讯，中国抗体-B(03681)发布公告，于2025年8月15日根据认购协议发行1.57亿股认购股份 予认购人。 ...

Group 1 - The company China Antibody-B (03681) announced the issuance of 157 million subscription shares to the subscribers based on the subscription agreement on August 15, 2025 [1]

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 中國抗體製藥有限公司 FF305 呈交日期： 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 普通股 | 證券代號 (如上市) | 03681 | 說明 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | | 事件 | 佔有關事件前的現有已發 | 每股發行/出售價 (註4) | 已發行股份總數 | ...

（於香港註冊成立的有限公司） （股份代號：3681） 根據一般授權認購新股份 — 個別完成 董事會欣然宣佈，由於認購協議所載先決條件已獲達成，若干認購事項已根據 各相關認購協議的條款及條件於二零二五年八月十五日完成。 緒言 茲提述中國抗體製藥有限公司（「本公司」）日期為二零二五年七月二十二日的公告 （「該公告」），內容有關根據一般授權認購本公司新股份。除另有所指外，本公告 所用詞彙與該公告所界定者具有相同涵義。除認購人的名稱及詳情外，每份認購 協議的條款相同。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 SinoMab BioScience Limited 中 國 抗 體 製 藥 有 限 公 司 完成個別認購新股份 董事會欣然宣佈，由於認購協議所載先決條件已獲達成，惟(i)本公司與認購人H 及(ii)本公司與認購人O的認購事項除外，故根據各相關認購協議的條款及條件， 二十 一(21) ...

截至2024年年报，中国抗体-B营业总收入202.6万元、净利润-1.85亿元。 8月15日，中国抗体-B(03681)盘中上涨9.57%，截至14:56，报3.55元/股，成交1.38亿元。 中国抗体制药有限公司专注于研发、生产和商业化基于单克隆抗体的生物制剂来治疗免疫性疾病，其中 旗舰产品SM03 (Suciraslimab) 是全球首款用于治疗类风湿关节炎的抗CD22单抗药物，正在全速进行商 业化进程。公司的其他关键数据包括2023年4月其SM03 (Suciraslimab)在中国进行治疗类风湿关节炎的 III期临床研究完成，并且在同年9月5日获得国家药品监督管理局接受其治疗类风湿关节炎的生物制品许 可申请，其生产基地在2024年1月完成了临床现场检查和生产质量管理规范检查。 本文源自：金融界 作者：行情君 ...

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company announced a three-year comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that the cooperation agreement provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The cooperation is designed to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] Group 2: Project-Driven Model - The collaboration will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This model allows the company to directly utilize the advanced laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets of Sun Yat-sen University Hong Kong Advanced Institute, which are critical for driving innovation in drug research and sustainable development [1] - The board views this strategic cooperation as a framework for mutual benefit, contributing to growth and ensuring long-term sustainability, aligning with the company's strategy to advance its pipeline of innovative drugs [1]

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company announced a three-year strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that the cooperation agreement provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The collaboration is designed to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] Group 2: Project-Driven Model - The cooperation will adopt a project-driven model, focusing on resource sharing and efficient communication as its core framework [1] - This model allows the company to directly utilize the advanced laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets of Sun Yat-sen University Hong Kong Advanced Institute, which are critical for driving innovation in drug research and sustainable development [1] - The board views this strategic partnership as a framework for mutual benefit, contributing to growth and ensuring long-term sustainability [1]

Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase, rising over 11% during trading, with a current price of 3.52 HKD and a trading volume of 106 million HKD, following the announcement of a strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute [1] Group 1: Strategic Cooperation - The company has entered into a three-year comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute, aimed at joint research and development in the biomedical field [1] - The board believes that this cooperation provides valuable opportunities for both parties to leverage their resources and expertise, achieving mutual benefits and synergies [1] - The agreement is seen as fair and reasonable, aligning with the overall interests of the company and its shareholders [1] Group 2: Objectives and Framework - The cooperation aims to accelerate the development of innovative drugs and promote the translation of research results into clinical applications globally [1] - The project-driven model will focus on resource sharing and efficient communication, allowing the company to utilize the advanced laboratory facilities, animal supply resources, and valuable data assets of the Sun Yat-sen University Hong Kong Advanced Institute [1] - This strategic partnership is expected to create a mutually beneficial framework that supports growth and ensures long-term sustainability, aligning with the company's strategy to advance its pipeline of innovative drugs [1]

Core Viewpoint - China Antibody-B (03681) has entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Hong Kong Advanced Institute of Science (SYSU-IAS) to enhance joint research and development in the biomedical field over a three-year period [1] Group 1: Strategic Cooperation - The cooperation agreement aims to leverage the strengths of both parties to accelerate the development of innovative drugs and facilitate the translation of research results into clinical applications globally [1] - The collaboration will adopt a project-driven model focusing on resource sharing and efficient communication [1] Group 2: Resource Utilization - The partnership allows the company to directly utilize SYSU-IAS's comprehensive laboratory facilities, experimental animal supply resources (especially non-primate animals), and valuable data assets [1] - These elements are considered key factors in promoting innovative drug research and ensuring the sustainable development of the company's R&D efforts [1]

Core Viewpoint - A comprehensive strategic cooperation agreement has been signed between China Antibody and the Hong Kong Advanced Institute of Zhongshan University, aiming to integrate research and industrial resources to advance biopharmaceutical innovation and clinical translation for better treatment options for global patients [3][4]. Group 1: Cooperation Agreement Details - The cooperation agreement includes five key areas: joint research, shared facility resources, full-chain technical support, drug development, and training and knowledge exchange [3]. - The collaboration aims to enhance professional research capabilities in treating degenerative diseases through training programs and personnel exchanges [3][4]. Group 2: Institutional Goals and Capabilities - The Hong Kong Advanced Institute of Zhongshan University focuses on addressing global medical challenges and aims to precisely connect research resources with industrial strengths [4]. - The institute possesses strong capabilities in animal model construction, regulatory expertise, and joint laboratory facilities, which will synergize with China Antibody's practical experience in antibody drug development [4]. - Established in October of the previous year, the institute integrates teaching, research, and technology transfer, with a focus on biomedicine, applied mathematics, and interdisciplinary humanities and social sciences [4].